title: Weight loss medications--where do they fit in?
abstract: BACKGROUND
  Obesity is a chronic disease requiring a similar long term approach to management as that of other chronic conditions.
  
  
  OBJECTIVE
  This article discusses the role of medications in the overall management of obesity.
  
  
  CONCLUSIONS
  Management needs to be multifaceted, aiming to alter the patient and family micro-environment to one favouring better weight control through sustainable behavioural changes to physical activity and diet. Weight loss medications may provide additional benefit. Currently we have only two medications suitable for long term therapy--orlistat and sibutramine. Sibutramine, which acts centrally to suppress appetite, has shown efficacy for up to 2 years. Orlistat, a lipase inhibitor, reduces fat absorption and has been shown to reduce and maintain weight for up to 4 years. The effect of these medications is modest, generally providing less than 5 kg weight loss when compared with placebo. Patients need to have realistic expectations and understand the benefits of sustained modest weight loss. It is important that weight loss medications are prescribed in combination with lifestyle modification.
authors.affiliation: Centre for Obesity Research and Education, Monash University, Victoria. john.dixon@med.monash.edu.au
authors.forename: John B
authors.initials: JB
authors.lastname: Dixon
mesh_terms: D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D002908:Chronic Disease; D003503:Cyclobutanes / Q000627:therapeutic use*; D004053:Diethylpropion / Q000627:therapeutic use; D006801:Humans; D007783:Lactones / Q000627:therapeutic use*; D009765:Obesity / Q000188:drug therapy*; D000077403:Orlistat; D010645:Phentermine / Q000627:therapeutic use; D015431:Weight Loss / Q000187:drug effects / Q000502:physiology*
chemical_list: D019440:Anti-Obesity Agents; D003503:Cyclobutanes; D007783:Lactones; D000077403:Orlistat; D010645:Phentermine; D004053:Diethylpropion; C058254:sibutramine